PMS-CYTARABINE
As listed in the register: PMS-CYTARABINE
20 mg · solution
- Prescription only
- Cancer treatments and immune-system medicines
- Active substance
- Cytarabine
- Made by
- Pharmascience Inc
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Cytarabine). It describes the substance, not this exact product.
Cell Culture Studies: Cytarabine is cytotoxic to a wide variety of proliferating mammalian cells in culture.
It exhibits cell phase specificity, primarily killing cells undergoing DNA synthesis (S-phase) and under certain conditions blocking the progression of cells from the G 1 phase to the S-phase.
Cellular Resistance and Sensitivity: Cytarabine is metabolized by deoxycytidine kinase and other nucleotide kinases to the nucleotide triphosphate, an effective inhibitor of DNA polymerase; it is inactivated by a pyrimidine nucleoside deaminase which converts it to the nontoxic uracil derivative.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-08-27
Safety of the active substance
From the US prescribing label for the same active substance (Cytarabine). It describes the substance, not this exact product.
WARNING Only physicians experienced in cancer chemotherapy should use Cytarabine Injection.
- Cytarabine is contraindicated in those patients who are hypersensitive to the drug.
Most Frequent Adverse Reactions: Anorexia, hepatic dysfunction, nausea, fever, vomiting, rash, diarrhea, thrombophlebitis, oral and anal inflammation or ulceration, bleeding (all sites).
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pharmascience Inc |
|---|---|
| Active substance | Cytarabine |
| Used in | Cancer treatments and immune-system medicines |
| Strength | 20 mg |
| Form | solution |
| Classification | L01BC01 · Cancer treatments and immune-system medicines |
| Route | intrathecal, intravenous, subcutaneous |
| Dispensing (as stated by the register) | PRESCRIPTION |
| Status | Dormant |
| Marketed | No — authorised but not currently marketed, according to the register |
| DIN | 02406764 |
| DPD drug code | 89144 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
2 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution2 products
- 20 mg
- 100 mg
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.